Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG PEN versus NOVOLOG MIX 70 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG PEN versus NOVOLOG MIX 70 30.
HUMALOG PEN vs NOVOLOG MIX 70/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways (e.g., PI3K/Akt) to promote glucose uptake in skeletal muscle and adipose tissue, inhibit hepatic gluconeogenesis, and regulate lipid and protein metabolism.
Biphasic insulin analog combining rapid-acting insulin aspart and intermediate-acting protamine-crystallized insulin aspart, which lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production.
Subcutaneously 0.5–1 unit/kg/day divided into multiple doses (usually 3 or more), administered 15 minutes before or immediately after meals.
Subcutaneous injection only. Typical total daily insulin dose ranges from 0.5 to 1.0 units/kg/day divided into two or three injections. Administer twice daily, with each dose given within 15 minutes before meals. Dose individualization based on glycemic targets and previous insulin regimen is required.
None Documented
None Documented
Approximately 0.5-1 hour (rapid; subcutaneous absorption rate-limited).
Insulin aspart (free component): ~1-2 hours; protamine-crystallized component: ~8-10 hours. Clinical context: Duration of action up to 24 hours due to the intermediate-acting component.
Renal: 60-80% of dose excreted as metabolites; remainder hepatobiliary and fecal.
Renal: 30-80% of dose excreted unchanged in urine for insulin aspart; for protamine-crystallized component, metabolism and renal elimination also occur. Biliary/fecal: Minor.
Category C
Category C
Insulin Analog
Insulin Analog